A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient heterozygous for the CYP2C9*3 allele. A 30-year-old woman with an artificial cardiac pacemaker was taking warfarin to prevent thromboembolism. This patient had an extremely elevated international normaliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Soo-Youn, Kim, June Soo, Kim, Jong-Won
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2005
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810600/
https://www.ncbi.nlm.nih.gov/pubmed/16385662
http://dx.doi.org/10.3349/ymj.2005.46.6.843
_version_ 1782176700405121024
author Lee, Soo-Youn
Kim, June Soo
Kim, Jong-Won
author_facet Lee, Soo-Youn
Kim, June Soo
Kim, Jong-Won
author_sort Lee, Soo-Youn
collection PubMed
description We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient heterozygous for the CYP2C9*3 allele. A 30-year-old woman with an artificial cardiac pacemaker was taking warfarin to prevent thromboembolism. This patient had an extremely elevated international normalized ratio (INR) of prothrombin time (PT) following standard doses of warfarin and experienced difficulties during the induction of anticoagulation. Genotyping for CYP2C9 revealed that this patient was an intermediate metabolizer with genotype CYP2C9*1/*3. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.
format Text
id pubmed-2810600
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-28106002010-01-26 A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9 Lee, Soo-Youn Kim, June Soo Kim, Jong-Won Yonsei Med J Case Report We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient heterozygous for the CYP2C9*3 allele. A 30-year-old woman with an artificial cardiac pacemaker was taking warfarin to prevent thromboembolism. This patient had an extremely elevated international normalized ratio (INR) of prothrombin time (PT) following standard doses of warfarin and experienced difficulties during the induction of anticoagulation. Genotyping for CYP2C9 revealed that this patient was an intermediate metabolizer with genotype CYP2C9*1/*3. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin. Yonsei University College of Medicine 2005-12-31 2005-12-31 /pmc/articles/PMC2810600/ /pubmed/16385662 http://dx.doi.org/10.3349/ymj.2005.46.6.843 Text en Copyright © 2005 The Yonsei University College of Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Lee, Soo-Youn
Kim, June Soo
Kim, Jong-Won
A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
title A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
title_full A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
title_fullStr A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
title_full_unstemmed A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
title_short A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
title_sort case of intolerance to warfarin dosing in an intermediate metabolizer of cyp2c9
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810600/
https://www.ncbi.nlm.nih.gov/pubmed/16385662
http://dx.doi.org/10.3349/ymj.2005.46.6.843
work_keys_str_mv AT leesooyoun acaseofintolerancetowarfarindosinginanintermediatemetabolizerofcyp2c9
AT kimjunesoo acaseofintolerancetowarfarindosinginanintermediatemetabolizerofcyp2c9
AT kimjongwon acaseofintolerancetowarfarindosinginanintermediatemetabolizerofcyp2c9
AT leesooyoun caseofintolerancetowarfarindosinginanintermediatemetabolizerofcyp2c9
AT kimjunesoo caseofintolerancetowarfarindosinginanintermediatemetabolizerofcyp2c9
AT kimjongwon caseofintolerancetowarfarindosinginanintermediatemetabolizerofcyp2c9

Ejemplares similares